Atea Pharmaceuticals, Inc.
3.2900+0.08 (+2.49%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · AVIR · USD
Key Stats
Market Cap
261.09MP/E (TTM)
-Basic EPS (TTM)
-1.62Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Atea Pharmaceuticals narrowed its Q2 net loss to $37.2M from $40.5M a year earlier, driven by a 12% drop in R&D expenses to $32.3M as COVID-19 trial costs wound down, though HCV Phase 3 ramp-up added $24.3M in external spend including a $5M Merck milestone. Operating loss improved 12% y/y to $41.3M, with stock-based comp down sharply to $4.7M from $12.7M, while interest income fell to $4.4M on lower balances. Cash and marketable securities stood at $379.7M at quarter-end, funding operations through 2027 after a 25% workforce cut saved $15M through 2027 and $14.1M share repurchases. Enrollment advances in C-Beyond and C-Forward trials for the bemnifosbuvir-ruzasvir regimen. Yet clinical delays remain a key risk.
8-K
HCV Phase 3 enrollment advances
Atea Pharmaceuticals advanced its global Phase 3 HCV program, with enrollment on track in C-BEYOND (US/Canada, started April 2025) and C-FORWARD (ex-North America, started June 2025), evaluating the bemnifosbuvir/ruzasvir regimen against sofosbuvir/velpatasvir for 8-12 week treatments. Phase 2 data confirmed 98% SVR12 in adherent patients, highlighting short duration and low drug interactions. Cash stood at $379.7 million as of June 30, 2025, down from $454.7 million year-end, while repurchasing $13.9 million in shares. Yet strategic review outcome remains uncertain.
8-K
Annual meeting results approved
Atea Pharmaceuticals held its 2025 Annual Meeting on June 20, with 87.6% of shares represented. Stockholders elected Bruno Lucidi, Polly Murphy, DVM, PhD, and Bruce Polsky, MD, MACP, FIDSA as Class II directors until 2028. They ratified KPMG LLP as auditors for the year ending December 31, 2025, and approved executive compensation on an advisory basis. Directors secured; oversight intact.
8-K
Atea Q1 loss narrows on HCV progress
Atea Pharmaceuticals reported Q1 2025 net loss of $34.3 million, down from $63.2 million last year, as R&D expenses halved to $29.6 million amid wrapping up COVID trials and ramping HCV Phase 3 startup. Cash reserves stand at $425.4 million, bolstering the ongoing C-BEYOND enrollment and mid-2025 C-FORWARD launch for its bemnifosbuvir-ruzasvir regimen, which hit 98% SVR12 in adherent Phase 2 patients. Workforce cuts save $15 million through 2027. Strategic review ongoing.
10-Q
Q1 FY2025 results
Atea Pharmaceuticals narrowed its Q1 FY2025 net loss to $34.3M from $63.2M y/y, driven by a 49% drop in R&D expenses to $29.6M as COVID-19 trial costs fell to $1.2M from $39.1M, while HCV external costs rose to $17.6M from $6.0M amid Phase 3 startup. Operating loss improved 44% to $39.0M y/y, with diluted EPS at -$0.40 versus -$0.75 y/y, reconciling to 85.2M weighted shares. Cash and equivalents climbed to $119.4M from $64.7M q/q, with total liquidity at $425.4M supporting operations through 2027 after a 25% workforce cut for $15M savings through 2027; no debt. In April 2025, enrollment began in the US/Canada Phase 3 HCV trial C-BEYOND, with a $5M Merck milestone due. Yet clinical trials remain an expensive, uncertain process.
ABUS
Arbutus Biopharma Corporation
4.61+0.03
ARMP
Armata Pharmaceuticals, Inc.
5.46+0.47
ATHA
Athira Pharma, Inc.
4.08-0.13
ATOS
Atossa Therapeutics, Inc.
0.88-0.06
ATYR
aTyr Pharma, Inc.
0.97+0.01
ENTA
Enanta Pharmaceuticals, Inc.
10.63+0.16
HEPA
Hepion Pharmaceuticals, Inc.
0.07+0.01
NNVC
NanoViricides, Inc.
1.86+0.33
VIR
Vir Biotechnology, Inc.
5.91-0.52
VIRX
Viracta Therapeutics, Inc.
0.01+0.00